SCHEMBL2404100

SCHEMBL2404100

O=C(C1CCC(NS(=O)(=O)c2ccc(F)c(Cl)c2)CC1)N1CCN(C2CCC2)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.47
KMT2A Q03164 3/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
IDH2 P48735 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MAPT P10636 4/20 0.44
TP53 P04637 3/20 0.44
POLB P06746 2/20 0.44
MEN1 O00255 2/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44
LMNA P02545 3/20 0.44
ALDH1A1 P00352 1/20 0.43
DRD2 P14416 1/20 0.43
ADRA1D P25100 1/20 0.43
ADRA1A P35348 1/20 0.43
ADRA1B P35368 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2404102 1.00 CNR1 (0.47) CNR1KMT2ATDP1L3MBTL1IDH2
SCHEMBL2405848 0.98 NPSR1 (0.47) CNR1KMT2ATDP1IDH2NPSR1
SCHEMBL2405845 0.98 NPSR1 (0.47) CNR1KMT2ATDP1IDH2NPSR1
SCHEMBL2401393 0.86 KMT2A (0.44) KMT2ATDP1L3MBTL1MAPTTP53
SCHEMBL2401388 0.86 KMT2A (0.44) KMT2ATDP1L3MBTL1MAPTTP53
SCHEMBL2400473 0.84 CNR1 (0.47) CNR1KMT2ATDP1IDH2NPSR1
SCHEMBL2404528 0.84 CNR1 (0.47) CNR1KMT2ATDP1IDH2NPSR1
SCHEMBL2400476 0.84 CNR1 (0.47) CNR1KMT2ATDP1IDH2NPSR1
SCHEMBL2404113 0.84 CNR1 (0.47) CNR1KMT2ATDP1IDH2NPSR1
SCHEMBL2404527 0.84 CNR1 (0.47) CNR1KMT2ATDP1IDH2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017773-B2 Cyclohexyl sulfonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2011-09-13 US disclosed
EP-1979322-B1 CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY HOFFMANN LA ROCHE (CH) 2010-09-01 EP disclosed
US-20100120791-A1 CYCLOHEXYL SULFONAMIDE DERIVATIVES NETTEKOVEN MATTHIAS 2010-05-13 US disclosed
EP-1979322-A1 CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2008-10-15 EP disclosed
WO-2007082840-A1 CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2007-07-26 WO disclosed
US-20070173511-A1 Cyclohexyl sulfonamide derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120791-A1 CYCLOHEXYL SULFONAMIDE DERIVATIVES HRH3, HRH4, HRH1 CNR1 8/4885KMT2A 338/4885TDP1 4241/4885
US-20070173511-A1 Cyclohexyl sulfonamide derivatives HRH3, HRH4, HRH1 CNR1 8/4885KMT2A 338/4885TDP1 4241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.